Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of CM326 in moderate-to-severe asthma
CTR20230693Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CM326 in asthma, sponsored by Keymed Biosciences. Started May 2023; status: active.
02
Drugs
CM326
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20230693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230693.